US FDA Makes Final Decision On 'Inordinate' Out-Of-State Compounding

 
• By Joanne S. Eglovitch

Under the US FDA’s final MOU on interstate compounding, states are given more time to decide whether to sign the agreement and investigate complaints of adverse events associated with drugs compounded by 503A pharmacies. Agreement draws mixed reactions from pharmacy groups. 

Contract parties sent memorandum of understanding (mou) document folder.
FDA's final offer of standard mou language on Interstate Compounding • Source: Shutterstock

More from Manufacturing

More from Compliance